HopeStage
Back to all studies
WithdrawnNCT00562055

Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

This study evaluates the safety and effectiveness of Atomoxetine for people with ADHD.

Medication studyAges 18–55
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of Atomoxetine for people with ADHD.

Who could participate?

This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateNovember 2007
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Not clearly listed
Age range
From 18 Years to 55 Years
Official registry ID
NCT00562055
Official title
Show the full official title

Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Recruitment & locations

Withdrawn

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of Atomoxetine for people with ADHD.

Who is behind this study?

The study sponsor is Pfizer.

Does this study involve medication?

Yes. The study involves medication, including Atomoxetine and PNU-165442G; [S,S]-reboxetine.

Who can participate?

This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies